anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
Family History Positive (FHP) for alcoholism will be given a single dose of AFQ056 (200 mg) then placebo in two separate experimental study visits separated by 1 week. Drug and Placebo administered 2 hours prior to the MRI and other measures.
<P>PROBLEM TO BE SOLVED: To obtain a new gene associated with formation, growth, differentiation, proliferation and maintenance of cartilage, tissue such as connective tissue and organ, a protein encoded by the same and a composition for treating diseases of cartilage or connective tissue.  <P>SOLUTION: The purified human SDF-5 protein and the method for producing the same are disclosed. The DNA molecule encoding a human SDF-5 protein is disclosed. The protein may be used in regulating the binding of Wnt gene to its receptor. In preferred embodiments, the protein may be used for inducing formation, growth, differentiation, proliferation and/or maintenance of chondrocyte and/or cartilage tissue, and for other tissue repair, such as pancreatic tissue repair.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
A reminder label system for attachment to a healthcare item and/or a patient. The reminder label system includes a label and a visual indicator. The label has pre-printed text corresponding to the healthcare item and/or the patient and further has a writeable surface to receive unique information about the healthcare item and/or the patient. The visual indicator is on the label and provides information relating to an event associated with the healthcare item and/or the patient. The visual indicator could provide any one of a number of different types of information including, but not limited to, time passage since activation of the indicator and exposure conditions of the indicator (e.g., temperature, radiation, sterilization, contamination, and so forth). Such a reminder label system can facilitate maintenance and patient care because it is detailed, secure, automatic, compliant, and workflow efficient.
A magnetic circumferentially-coupled implantable pump (9) is disclosed herein. A magnetically coupled implantable actuation system utilizes a magneticallyt-coupled drive mechanism (4) configured to generate power for implantable medical devices. One variation generally comprise a drive magnet (25) having a first radius and adapted to rotate about a longitudinal axis when urged, and a driven magnet (26) defining a second radius, which is less than the first radius. This driven magnet is adapted to be implanted within a body rotate about the longitudinal axis when coaxially positioned within a receiving cavity defined by the drive magnet such that magnetic coupling occurs circurnferentially between the driven magnet and the drive magnet. Another variation utilizes elongate bar magnets (1, 5) configured to rotate about a pivot. An optional anchor (12) can be used to secure the implanted driven magnet housing against any rotational forces or moments by securing the housing within the subcutaneous layer.
Elderly patients (aged 65 years or older) may have increased sensitivity to Pentazocine and Naloxone Tablets. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Pentazocine and Naloxone Tablets slowly in geriatric patients and frequently reevaluate the patient [see WARNINGS].

Pentazocine and naltrexone are known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Inject a full dose of GnRH-a in 1st-3rd day of menstruation (leuprorelin acetate, injection, 3.75mg), the level of E2, P, LH in peripheral blood and the number of follicles in bilateral internal ovarian sinuses were monitored 32-38 days after the depression. If the pituitary desensitization was achieved, Gn (recombinant human follicle stimulating hormone or urofollicle stimulating hormone, injection, 75-300iu) was used for contralled hyperstimulation, when the diameter of 2 follicles was ≥ 18mm，hCG (human chorionic gonadotropin, injection, 4000-10000IU) was used to trigger and retrieve the oocyte. Selective single blastocyst transplantation was performed on the 4th-6th day after the oocyte retrieved. β-hCG was detected on the 12th day after embryo transplantation, and pregnancy or not was judged. If patients get pregnancy, follow-up was continued until the 42nd day after baby delivery.
A method, system and apparatus for the monitoring, diagnosis and evaluation of the state of a dynamic system is disclosed. This method and system provides the processing means for receiving sensed and/or simulated data, converting such data into a displayable object format and displaying such objects in a manner such that the interrelationships between the respective variables can be correlated and identified by a user. This invention provides for the rapid cognitive grasp of the overall state of a critical function with respect to a dynamic system. The system provides for displayed objects, which change in real-time to show the changes of the functions of the system. It is a highly flexible system which works with a wide variety of applications, including biological systems, environmental systems, engineering systems, economic systems, mechanical systems, chemical systems and the like. In particular, this invention is directed to the processing and display of drug data for the use of doctors in the process of monitoring or administering drugs to patients.
In the last decade, fatigue in clinical populations has been re-conceptualized, including dimensions such as perceived fatigue (trait and state fatigue) and fatigability. The aim of this study was to evaluate different expressions of fatigue in Spinal Cord Injury (SCI) and Multiple Sclerosis (MS) participants compared to able-bodied controls, during activities of daily living, especially during gait. A total of 67 participants were included in this study (23 with SCI, 23 with MS, and 21 able-bodied controls). All participants performed two functional tests (6-Minute Walk Test and 10-Meter Walk Test) and they completed the Fatigue Severity Scale (FSS). The rate of trait fatigue was different between groups, with MS participants showing the highest rate. Moreover, scores on functional tests and state fatigue were different between groups after the tests. Our results indicate that trait fatigue and state fatigue in individuals with SCI and MS are different with respect to able-bodied population. Both SCI and MS groups experienced more trait fatigue than control group in daily life. In addition, walking tasks produced similar levels of state fatigue between healthy people and patients with MS/SCI. However, these tests induced longer-lasting levels of state fatigue in the patients.
A method, system and apparatus is provided for identifying pharmaceutical products. A database of known pharmaceuticals is provided with links to virtual 3D models of each pharmaceutical. When a pill needs to be identified, an image of the pill is transmitted to the database CPU. The CPU screens out non-matching records and obtains perspective data. based on the orientation of the pill. The CPU manipulates a 3D model into the same perspective as the pill to facilitate identification.
The present invention is directed to a face mask comprising a multi-layer filter material. One or more antimicrobial and/or hydrophilic and/or stain release agents are adhered to a textile material that forms the outer layers of the multi-layerfilter material. The agent(s) is/are adhered to the textile material in such a manner that they are not released from the textile material even if the face mask is washed, so that the face mask as such is re-usable. The particular arrangement of textile layers of the face mask according to the present invention also allows that the face mask can be washed. That is, the textile and the overall structure of the face mask is preserved albeit the physical stress applied during washing. In preferred embodiments, where one or more antimicrobial agents are adhered to the textile material, the face mask can be used to protect the wearer against airborne particulate and microbial pollution, and, in particular, sanitize the inhaled air. Likewise, the environment, such as other persons, are protected from particles and microbes that are exhaled by the wearer of a face mask according to the present invention. Washability and/or usability of the textile material within the multi-layerfilter material of the face mask is/are improved when one or more hydrophilic and/or stain release agents are adhered to the textile material, which is particularly advantageous to ensure that the face mask is rendered as clean as possible during wash, i.e. that absorbed or adsorbed stains are released from the textile. The invention further relates to a method of finishing a textile material by applying and binding antimicrobial and/or hydrophilic and/or stain release agents to the textile material so that the agents are essentially irreversibly adhered to the finished textile material.
The present invention involves a dietary supplement that can be used as a weight loss composition. The composition comprises of an essentially dry mixture of chromium, L-carnitine, gamma-linolenic acid, (-) hydroxycitric acid, choline, inositol, antioxidants and herbs. The preferred antioxidants are Coenzyme Q10 and the herbs are ginkgo biloba leaves. The essentially dry mixture can be prepared as a beverage and delivered enterally. The present invention also involves a method for inducing weight loss in a mammal. The method involves administering to a mammal, preferably a human, a weight loss inducing effective amount of the above described essentially dry mixture. The weight loss inducing effective amount of the above composition is administered daily in at least two separate portions of 7.325 grams each.
Chronic Kidney Disease (CKD) stands as a substantial challenge within the global health landscape. The elevated metabolic demands essential for sustaining normal kidney function have propelled an increasing interest in unraveling the intricate relationship between mitochondrial dysfunction and CKD. However, the authentic causal relationship between these two factors remains to be conclusively elucidated. This study endeavors to address this knowledge gap through the Mendelian Randomization (MR) method. We utilized large-scale QTL datasets (including 31,684 eQTLs samples, 1980 mQTLs samples, and 35,559 pQTLs samples) to precisely identify key genes related to mitochondrial function as exposure factors. Subsequently, we employed GWAS datasets (comprising 480,698 CKD samples and 1,004,040 eGFRcrea samples) as outcome factors. Through a comprehensive multi-level analysis (encompassing expression, methylation, and protein quantification loci), we evaluated the causal impact of these genes on CKD and estimated glomerular filtration rate (eGFR). The integration and validation of diverse genetic data, complemented by the application of co-localization analysis, bi-directional MR analysis, and various MR methods, notably including inverse variance weighted, have collectively strengthened our confidence in the robustness of these findings. Lastly, we validate the outcomes through examination in human RNA sequencing datasets encompassing various subtypes of CKD. This study unveils significant associations between the glycine amidinotransferase (GATM) and CKD, as well as eGFR. Notably, an augmentation in GATM gene and protein expression corresponds to a diminished risk of CKD, whereas distinct methylation patterns imply an increased risk. Furthermore, a discernible reduction in GATM expression is observed across diverse pathological subtypes of CKD, exhibiting a noteworthy positive correlation with GFR. These findings establish a causal relationship between GATM and CKD, thereby highlighting its potential as a therapeutic target. This insight lays the foundation for the development of potential therapeutic interventions for CKD, presenting substantial clinical promise.
In three placebo-controlled, 12-week trials, the incidence of consecutive elevations (≥3 X ULN) in serum transaminases was 1.7% overall for patients treated with Ezetimibe and Simvastatin Tablets and appeared to be dose-related with an incidence of 2.6% for patients treated with Ezetimibe and Simvastatin Tablets 10/80. In controlled long-term (48 week) extensions, which included both newly-treated and previously-treated patients, the incidence of consecutive elevations (≥3 X ULN) in serum transaminases was 1.8% overall and 3.6% for patients treated with Ezetimibe and Simvastatin Tablets 10/80. These elevations in transaminases were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment. 

In SHARP, 9270 patients with chronic kidney disease were allocated to receive Ezetimibe and Simvastatin Tablets 10/20 mg daily (n=4650), or placebo (n=4620). During a median follow-up period of 4.9 years, the incidence of consecutive elevations of transaminases (>3 X ULN) was 0.7% for Ezetimibe and Simvastatin Tablets and 0.6% for placebo. 

It is recommended that liver function tests be performed before the initiation of treatment with Ezetimibe and Simvastatin Tablets, and thereafter when clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including simvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with Ezetimibe and Simvastatin Tablets, promptly interrupt therapy. If an alternate etiology is not found do not restart Ezetimibe and Simvastatin Tablets. Note that ALT may emanate from muscle, therefore ALT rising with CK may indicate myopathy [see Warnings and Precautions (5.1)]. 

Ezetimibe and Simvastatin Tablets should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained persistent transaminase elevations are contraindications to the use of Ezetimibe and Simvastatin Tablets.
Participating caregivers and care partners will receive mindfulness training in 8 weekly telephone sessions plus one retreat. Respite care for the care recipient is provided for the retreat.
Gallbladder cancer is the most common malignant biliary tract tumor. The main risk factors for gallbladder cancer include gallstones, gallbladder polyps, gallbladder adenomas, chronic inflammation of the gallbladder, etc. However, recently, there is still a lack of evaluation data on relevant risk factors. Therefore, on the basis of large-scale epidemiological investigations, large-scale prospective studies are needed to further clarify the level of risk factors associated with gallbladder cancer. With the development of modern imaging technology and deep understanding of gallbladder diseases, the detection rate of benign gallbladder lesions (cacerous polyps, gallbladder adenomyosis, gallbladder adenoma, gallstones, etc.) has increased year by year, and some benign gallbladder lesions can pass A series of pathophysiological processes have gradually evolved into gallbladder cancer. This study aimed to establish a prospective cohort of benign gallbladder disease, to explore the correlation, intervention time and socioeconomic benefits of benign gallbladder disease and gallbladder cancer. In order to further understand the current trend and diagnosis and treatment of benign gallbladder disease in China, the Chinese Society of Surgery Branch of the Chinese Society of Surgery will launch a national epidemiological survey of gallbladder cancer (2018). This study will provide a more detailed basis for the diagnosis and treatment of benign gallbladder disease in China.
Although corticosteroids remain the mainstay of therapy for intraocular inflammation, many patients are intolerant or resistant to corticosteroid therapy. In these patients, other immunosuppressive agents have been employed to control potentially sight-threatening uveitis. Nevertheless, ideal therapy for these patients remains elusive, and there is a need for new immunosuppressive agents with varying modes of action and side effect profiles. Leflunomide, an isoxazole derivative, has profound immunosuppressive activity. Leflunomide inhibits autoimmune disease in animal models and has been used to treat patients with rheumatoid arthritis (RA). We propose a randomized masked pilot trial of leflunomide versus placebo for the treatment of uveitis. Sixteen patients 16 years of age or older with active intermediate, posterior, or panuveitis will be randomly assigned to receive prednisone and leflunomide or prednisone and placebo. Patients will then have the prednisone tapered according to a standardized schedule. The primary purpose of the study is to investigate the safety and efficacy of leflunomide versus placebo. The primary safety endpoint is the frequency of any of the following: abdominal pain, diarrhea, skin rash, hypertension, and alopecia. In addition, weight loss distributions and change in liver function tests will be described. The primary efficacy endpoint is any one or more of the following (1) a decrease of 10 or more letters in visual acuity from the baseline score for any reason, or (2) inability to taper prednisone to 10 mg qd by week 16 post randomization, or (3) inability to maintain the prednisone taper through Month 6 or Month 12, or (4) the addition of systemic therapy to treat ocular inflammatory disease. Secondary outcomes will include change in vitreous haze and presence or absence of cystoid macular edema.
The participants in the group were given PNF contract- relax stretching using the standard protocol. One trial had two isometric contractions each followed by five seconds muscle stretch and there was a total of four trials. Total of 12 sessions in 4 weeks (3sessions/week).
A transdermal therapeutic system using a subsaturated matrix is provided having improved approved release characteristics. Reinforcing means preferably in the form of a fabric are embedded in the upper surface of the subsaturated matrix. At least a portion of the reinforcing means is selected such that the active agent to be delivered to the skin has a solubility, Cr therein which is lower than the initial solubility Co of the agent in the matrix. In addition, the relationship between the diffusion coefficients of the agent in the matrix Dm and the portion of reinforcing means Dr and the solubilities is given by the relationship: DrxCr<DmxCo. In operation the agent dissolved in the reinforcing means acts as a secondary reservoir improving the release characteristics of the system. Specific embodiments of the invention are particularly adapted for scrotal and labial delivery of drugs such as testosterone and progesterone.
PROBLEM TO BE SOLVED: To provide a deodorant which is highly effective in deodorizing every kind of bad smells categorized into a sulfur group, a nitrogen group, an aldehyde group and an organic acid group. SOLUTION: This deodorant is comprised of citrus junos essential oil and/or synthetic citrus junos oil. As the citrus junos essential oil, essential oil extracted from the pericarp or the pericarp and the pulp of a citrus junos by means of a publicly known steam distillation method can be used. The following components are included in the citrus junos essential oil such as; limonene, nonanol, decanol, dodecanal, nerol, geraniol, carbeol, perilla alcohol, perilla aldehyde, 2,4-decadienal, methyl jasmonate, etc. As for the synthetic citrus junos oil, such an oil as prepared by a publicly known method so that the oil is scented with citrus junos can be used. The components of the synthetic oil are mixed based on the analysed components of the natural citrus junos oil (essential oil) so that the synthetic oil has a citrus junos scent.  And if the prepared scent is insufficient, an essence which is not confirmed by the analysis may be added to obtain the lacked scent if necessary.
A medical cost containment system for ensuring that the anticipated cost savings from utilization review (UR) agreements are actually realized. The UR agreements are essentially contractual agreements that specify the type and quantity of medical treatments relating to a specific claim resulting from a specific injury. Each UR agreement comprises a claim number, a procedure code describing the particular medical service authorized, and some indication as to dates or quantity of service authorized. All of the UR agreements are stored in a UR database. When a medical bill is received by the insurance company, the bill is entered in to the computer. The cost containment system searches all UR agreements in the UR database which have the same claim number as the claim number on the bill. For each item in the medical bill, the system finds the UR agreement which most closely matches the procedure code in the line item and various other criteria, such as the dates of treatment. The system then checks to ensure that the item in the bill is authorized by the UR agreement. If the item is authorized, then payment is made. If the item is not authorized, then the item is flagged for further review.
Portable patient communicators (PPCs) comprise a first radio configured to communicate wirelessly with a patient implantable medical device (PIMD) associated with the PPC and a second radio configured to communicate wirelessly with a network. Memory is configured to store at least first information about wireless connectivity between the PPC and its associated PIMD. A processor is coupled to the memory and the first and second radios. A power source is configured to supply power to components of the PPC. The processor is configured to coordinate discontinuous communication between the PPC and its associated PIMD via the first radio and coordinate discontinuous communication between the PPC and the network via the second radio. The processor is configured to coordinate wireless transmission of the first information to a remote server via the network, and the remote server receives second information about wireless connectivity between each of the PPCs and the network.